Check out the latest news from Cinclus Pharma
Two abstracts from Cinclus Pharma's phase II study, LEED, on its leading drug candidate linaprazan glurate, developed for the treatment of moderate to severe erosive GERD ("eGERD"), are being presented at the leading gastro conference United European Gastroenterology ("UEG") 14 – 17 October 2023. One of the abstracts focuses on linaprazan glurate's effectiveness, the other one on its safety.
Read more
Cinclus Pharma's co-founder and Chairman of the Board, Lennart Hansson, has long experience from leading positions at various biotech and pharmaceutical companies. He has also worked at AstraZeneca on gastrointestinal diseases and has served on more than 30 company boards. At Cinclus Pharma, all this experience is now put to good use.
Read more
Christer Ahlberg, CEO of Cinclus Pharma, was invited to present the company's latest updates and the development of linaprazan glurate at the ABGSC Life Science Summit on May 30-31, 2023.
Read more